VTAK Stock Analysis: Buy, Sell, or Hold?
VTAK - Catheter Precision, Inc.
$0.20
-0.01 (-3.54%)
▼
5d:
-11.45%
30d:
-23.14%
90d:
-76.19%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 17, 2026
0d
Get Alerted When VTAK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: VTAK is down 11.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: VTAK is down 11.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: VTAK is currently trading at $0.20, which is considered oversold relative to its 30-day fair value range of $0.22 to $0.48.
Technical Outlook: Technically, VTAK is in a strong downtrend. Immediate support is located at $0.19, while resistance sits at $0.31. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: VTAK scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.00 (+850.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VTAK is in a strong downtrend. Immediate support is located at $0.19, while resistance sits at $0.31. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: VTAK scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.00 (+850.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.22 -
$0.48
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 850.6% below Wall St target ($2.00)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.22 -
$0.48
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.19
Resistance Level
$0.31
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.66
Wall Street Target
$2.00
(+850.6%)
Revenue Growth (YoY)
380.7%
Share & Embed Analysis
Last updated: August 24, 2026 1:30 PM ET
Data refreshes hourly during market hours. Next update: 2:30 PM
Data refreshes hourly during market hours. Next update: 2:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VTAK showing a specific setup today?
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 31 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 37 SELL |
